| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total assets | 6,973 | 6,667 | ||
| Total current liabilities | 3,478 | 3,970 | ||
| Warrant liability | 0 | 2 | ||
| Contingent consideration obligation | - | 75 | ||
| Other noncurrent liabilities | 283 | - | ||
| Total liabilities | 3,761 | 4,047 | ||
| Series a convertible preferred stock, 0.01 par value, 7,000,000 shares authorized 200,000 issued and outstanding at september 30, 2025 and december 31, 2024-Series APreferred Stock | 2 | 2 | ||
| Common stock, 0.01 par value 280,000,000 shares authorized 9,119,152 and 2,768,646 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 91 | 48 | ||
| Additional paid-in capital | 146,945 | 143,528 | ||
| Accumulated deficit | -143,826 | -140,958 | ||
| Total stockholders' equity | 3,212 | 2,620 | ||
| Total liabilities and stockholders' equity | 6,973 | 6,667 | ||
PALISADE BIO, INC. (PALI)
PALISADE BIO, INC. (PALI)